- Home
- Equipment
- asia middle east
- breast ai reduces false positives
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- India
- Indonesia
- Iran
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- North Korea
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Breast Ai Reduces False Positives Equipment Supplied In Asia Middle East
5 equipment items found
Manufactured by:Meyn Food Processing Technology B.V. based inOostzaan, NETHERLANDS
Meyn’s opening machine, with its patented scissors mechanism, can handle a wide weight range within one machine setting. This is partly due to the fact that the processing unit is uniquely positioned against the keel bone before cutting. This positively affects product quality as the breasts remain perfectly covered with skin. The typical design of the centering bracket results in a very ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
??? (trastuzumab, Zercepac in the EU) was successfully launched in China and Europe, becoming the first Chinese mAb biosimilar entering both the EU and China market. It is indicated for the treatment of HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer, which corresponds to all the approved indications of the trastuzumab originator. ??? is certificated by ...
Manufactured by:DK Medical Systems based inSeocho-gu, SOUTH KOREA
ELMA-T3 is High Frequency Inverter Typeì˜ Mammography X-Ray ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
ENHERTU (5.4 mg/kg) is approved in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a (or one or more) prior antiHER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the ...
by:OncoStem Diagnostics Pvt. Ltd. based inBengaluru, INDIA
CanAssist Breast is a prognostic test developed by OncoStem that classifies the patients as ‘low-risk’ or ‘high-risk’ based on the patient’s risk of breast cancer recurrence over five years. CanAssist Breast provides information about the risk of recurrence of early-stage, hormone receptor-positive breast cancer patients. This test analyses critical ...